Entia Biosciences CEO Dr. Hausman to Represent GROH(R) at Cosmoprof North America

PORTLAND, OR / ACCESSWIRE / July 9, 2015 / Entia Biosciences, Inc. (OTCQB: ERGO), is excited to announce Dr. Marvin S. Hausman, MD and CEO will be representing the Company’s GROH(R) Professional brand of hair and skin care products at Cosmoprof North America (CPNA), the largest international B2B beauty event in the Americas.

Dr. Hausman and his team have created a revolutionary ‘Smart Nutrient Technology’ that combines natural formulations with the body’s own genetic-transport system to hyper-target hair and skin cells. “GROH’s Smart Nutrient Technology represents an evolution in natural and organic products from safe to safe and effective,” says Dr. Hausman.

The rise in consumer awareness and demand for effective scalp treatments that promote a healthy scalp, foster growth and address the stress and irritation caused by harsh chemically-based in-salon treatments, has moved GROH’s Ergo Boost product line to the center stage of Professional Beauty. GROH’s smart nutrient technology has been featured in a host of editorial publications, including: American Salon, Beauty Launch Pad, Beauty Blitz, Divalicious, Hollywood Life, Girlie Girl Army, and many others, all touting the many health and lifestyle benefits of the GROH(R) system and how it can greatly improve the guest experience and satisfaction.

GROH(R) is a boutique medical-luxury line available for retail through professional salon and day spas nationwide. The line is powered by an exclusive patented light enrichment technology that naturally enhances the nutrient capacity of Ergocalciferol (Vitamin D2) within a signature blend of high-potency mushrooms that are rich in Ergothioneine and sourced from around the globe. These clinically proven bio-nutrients are delivered directly to the cellular level of the body. The aim: to prolong the skin’s youthful appearance by supporting its vital functions – hydration, nutrition, protection, and rejuvenation. Products include Ergo Boost Hair & Scalp Conditioning Treatment ($59), Daily Replenishing Supplement ($39), Skin Recharge Cleansing Bar (2 bars/$22), and Skin Repair Treatment ($42). The GROH(R) system works from both the inside out and outside in, in synergy with one’s existing regimen and favorite products to promote a healthy lifestyle.

Meet Dr. Hausman

If your salon or network has a passion for enriching the lives of your guests we would like to invite you to meet Dr. Hausman and team.

To Schedule Contact:

Devin Andres at 503-974-0122 or email info@mygroh.com.

GROH(R) Results & Expectations

With regular use, the GROH(R) Ergo Boost product line has been shown to promote thicker, stronger hair and lashes, healthier skin, and increased nail strength and growth. For more information on the science behind this revolutionary new approach to health and beauty, please visit www.myGROH.com.

Entia Biosciences’ technologies have been proven in durable clinical trials to provide real benefits. In a recent study, subjects were instructed to take GROH(R) supplements daily and apply the ErgoBoost Treatment to their hair and scalp. The subjects immediately reported softer, shinier, and smoother hair, regardless of baseline conditions, demonstrating an immediate benefit.

After six weeks, the subjects also reported a decrease in hair loss and an increase in thickness and volume. After three months, subjects also reported decreased hair loss (88%), faster hair growth (75%), increased hair thickness (75%), decreased hair breakage (100%), and increased hair volume (93.5%). These results are especially exceptional given the significant response rates seen.

About Entia Biosciences, Inc.

Entia Biosciences, a leading biotechnology company, is an authority on the clinical effects of oxidative stress and free radical reactions and is bringing this expertise to food science, biotechnology and the field of nutrigenomics. Headquartered in Portland, Oregon. Entia identifies, scientifically validates, patents, and commercializes solutions that target unmet needs for the multi-billion dollar health and beauty markets.

Entia’s dedication to developing novel and organic therapies, utilizing its ErgoD2(R) technology, for severe medical conditions is not going unnoticed. In 2014, the company successfully secured a grant from the Michael J. Fox Foundation (MJFF) for Parkinson’s Research to evaluate the impact of the Medical Food ErgoD2(R) on Alpha-synuclein and Iron Levels. Furthermore, the Company’s Ergothioneine collaboration with the University of Hong Kong on ‘Protective Effects of Ergothioneine in Human Endothelial Cells’, was published in the September 2014 issue of The Journal of Pharmacology and Experimental Therapeutics.

About Cosmoprof North America (CPNA)

Cosmoprof North America is a trade show for beauty industry professionals ONLY. This event is not open to the general public. The event is focused in particular on the distributors, OTC’s, manufacturers and buyers of professional beauty products and retail stores. Attendees are allowed entrance into all three show pavilions.

This year’s CPNA event expects more than 27,000 attendees from over 100 countries worldwide and will play host to nearly 1,000 exhibitors. In addition to its renowned show pavilions and heavy schedule of industry-relevant conferences, CPNA is set to debut multiple new programs on the forefront of innovation. For more information or to register, visit www.cosmoprofnorthamerica.com. Event information and exhibitor updates are also posted on Facebook, Twitter and Instagram (@COSMOPROFNA).

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences with the Securities and Exchange Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2014 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov . The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

CONTACT:

For more information, please visit our website at www.entiabio.com or contact:

Devin Andres
Chief Operating Officer
Entia Biosciences Inc.
13565 SW Tualatin-Sherwood Rd.
Sherwood, OR 97140
(503) 334-3575
info@entiabio.com

SOURCE: Entia Biosciences, Inc.

ReleaseID: 430474